Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, Yale School of Public Health Partner to Update Saliva-Based Coronavirus Test

NEW YORK — Precision medicine firm Tempus said on Monday that it has partnered with the Yale School of Public Health to refine a saliva-based test for SARS-CoV-2.

The test, called SalivaDirect, uses dualplex RT-qPCR to detect SARS-CoV-2 RNA in saliva samples without the need for special types of swabs or collection devices, and does not require a separate nucleic acid extraction step. It was developed at Yale and received Emergency Use Authorization from the US Food and Drug Administration in August.

Under the terms of the deal, Tempus and Yale will further develop the test to enable at-home sample collection and to enable combination testing for SARS-CoV-2 and influenza. The partners noted that new iterations of the test will require FDA review.

Additional terms were not disclosed.

"Expanded at-home testing is critical to help control the pandemic and reduce future waves of COVID-19 infection," Tempus CSO Joel Dudley said in a statement.

In October, Chicago-based Tempus received FDA EUA for a PCR-based SARS-CoV-2 test it developed with Alimetrix. The firm also recently began an effort to structure and aggregate real-world clinical and genomic data from up to 50,000 COVID-positive patients with academic partners to better understand the disease and how it affects different people.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.